Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Baumann

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Swiss Medical Weekly|July 4, 2013
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in SwitzerlandWaldemar Greil, Anne Häberle, Thomas Schuhmann, et al.
Journal of Affective Disorders|July 29, 2014
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depressionJ Craig Nelson, Pierre Baumann, Kevin Delucchi, et al.
The International Journal of Neuropsychopharmacology|May 10, 2001
Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequencesGuido Bondolfi, Catherine Lissner, Markus Kosel, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label studyYves Le Bloc'h, Pierre Baumann, Michael Stigler, et al.
Therapeutic Drug Monitoring|September 14, 2011
Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scaleSonja Brünen, Philippe D Vincent, Pierre Baumann, et al.
Therapeutic Drug Monitoring|July 17, 2004
Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MSErik Paus, Michèle Jonzier-Perey, Nathalie Cochard, et al.
Therapeutic Drug Monitoring|July 27, 2005
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patientsGuido Bondolfi, Françoise Morel, Séverine Crettol, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 7, 2016
A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in EuropePierre Baumann, Marie Spies, Hans-Jürgen Möller, et al.
The International Journal of Neuropsychopharmacology|March 24, 2005
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopramGeorg Nikisch, Hans Agren, Chin B Eap, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic statusPierre Baumann, Rémy Barbe, Assia Vabre-Bogdalova, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Swiss Medical Weekly|July 4, 2013
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in SwitzerlandWaldemar Greil, Anne Häberle, Thomas Schuhmann, et al.
Journal of Affective Disorders|July 29, 2014
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depressionJ Craig Nelson, Pierre Baumann, Kevin Delucchi, et al.
The International Journal of Neuropsychopharmacology|May 10, 2001
Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequencesGuido Bondolfi, Catherine Lissner, Markus Kosel, et al.
International Journal of Psychiatry in Clinical Practice|June 18, 2014
Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label studyYves Le Bloc'h, Pierre Baumann, Michael Stigler, et al.
Therapeutic Drug Monitoring|September 14, 2011
Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scaleSonja Brünen, Philippe D Vincent, Pierre Baumann, et al.
Therapeutic Drug Monitoring|July 17, 2004
Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MSErik Paus, Michèle Jonzier-Perey, Nathalie Cochard, et al.
Therapeutic Drug Monitoring|July 27, 2005
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patientsGuido Bondolfi, Françoise Morel, Séverine Crettol, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 7, 2016
A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in EuropePierre Baumann, Marie Spies, Hans-Jürgen Möller, et al.
The International Journal of Neuropsychopharmacology|March 24, 2005
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopramGeorg Nikisch, Hans Agren, Chin B Eap, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic statusPierre Baumann, Rémy Barbe, Assia Vabre-Bogdalova, et al.
Pageof 10